Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low- versus conventional-background-dose oxycodone PCIA with ropivacaine intercostal nerve block after thoracoscopic radical lung cancer surgery
ChiCTR1800016369Phase 4Recruiting
- Sponsor
- Key Laboratory of Carcinogenesis and Translational Research
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of oxycodone and ropivacaine in postoperative pain (2 arms), sponsored by Key Laboratory of Carcinogenesis and Translational Research. Primary endpoint: VAS postoperative score. Started May 2018; status: recruiting.
02
Drugs
oxycodoneropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR1800016369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016369.